Burberry no longer in talks with Interparfums
Burberry, the iconic British luxury brand, announced on Friday that discussions with Interparfums regarding the possible termination of their licence agreement have ended.
Burberry, the iconic British luxury brand, announced on Friday that discussions with Interparfums regarding the possible termination of their licence agreement have ended.
Interparfums is currently the exclusive worldwide licensee for Burberry fragrance and beauty products.
The firm announced on July 17th that it was talking with the global fragrance company about ending their near 20-year licence agreement by exercising its option to buy out for €181m.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Burberry said that it wanted to establish a "new operating model" for the fragrance business and the move would be an attempt to "maintain flexibility in pursuing its objective to develop fully this business in the future."
Nevertheless, Burberry revealed on Friday that it is no longer in talks with Interparfums: "Burberry continues to pursue various strategic options to develop fully its fragrance and beauty business in the future," the company said in a statement.
BC
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Energy bills to rise by 1.2% in January 2025
Energy bills are set to rise 1.2% in the New Year when the latest energy price cap comes into play, Ofgem has confirmed
By Dan McEvoy Published
-
Should you invest in Trainline?
Ticket seller Trainline offers a useful service – and good prospects for investors
By Dr Matthew Partridge Published